On February 23, 2018, the FDA will make a decision to approve or not to approve KemPharm Inc.’s (KMPH) abuse-deterrent product candidate Apadaz for the short-term management of acute pain. Apadaz is an immediate-release fixed-dose combination product consisting of benzhydrocodone hydrochloride, a prodrug of hydrocodone and benzoic acid, and acetaminophen.The U.S. regulatory agency had refused to approve Apadaz in June 2016.KMPH closed Thursday’s (Jan.25) trading at $5.50, down 0.90%.